TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05469490

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT is specialize radiation that is effective for ablating tumors at primary and metastatic locations that increases antigen uptake/processing/presentation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: navoximod
Description: A small molecule inhibitor with potent inhibition of IDO1 enzymatic activity as shown both in vitro and in vivo. As the main function of IDO1 is the regulation of acquired immune tolerance, and its expression in tumor- and dendritic cells in tumor draining lymph nodes negatively correlates with cancer prognosis and survival, navoximod-mediated IDO1 inhibition may restore immune reactivity towards tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLG802 (indoximod Prodrug)
Description: An anti-tumor immunomodulator with the active ingredient of 1-methyl-D-tryptophan (NSC- 721782, 1-MT), which is an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that increases the bioavailability of indoximod by leveraging existing mechanisms of absorption, increasing the exposure of indoximod.
Study: NCT05320042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric
Description: kalifilcon A Daily Disposable Toric

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra for Astigmatism Contact Lenses
Description: Ultra for Astigmatism Contact Lenses
Study: NCT05414604

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D spine CT
Description: CT scan of the spine
Study: NCT04971655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy will be applied throughout diabetes education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered to individuals as an option and will be listened to throughout the process. Instrumental works will be uploaded to the computer by the researchers and will be played on the loudspeaker during the training.
Study: NCT05191784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered by intravenous (IV) injection
Study: NCT05528848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfentanil, C-11
Description: Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfentanil, C-11
Description: Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfentanil, C-11
Description: Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide Hydrochloride
Description: Loperamide is an FDA- approved, over-the-counter drug for the control and symptomatic relief of acute or chronic diarrhea given orally prior to the optional HC third PET/CT scan only.
Study: NCT05357495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective Posner fMRI frustration induction task
Description: During the frustration induction paradigm, children play a game with monetary reward. The game is rigged, thus inducing frustration. The control task does not have any reward component. All participants complete both the control task scanning session and the frustration induction scanning session.
Study: NCT05802355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Diaphragm Release
Description: The participant was supine, with his or her limbs relaxed. With the therapist's forearms aligned toward the participant's shoulders, the therapist gradually increased the depth of contact inside the costal margin during the subsequent respiratory cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: Respiratory re-training was given to participants in control group in form of slow and deep diaphragmatic breathing, exhalation through the nose with pursed lips (the participants were trained to emphasis on expiratory pressure against pursed lips), Breathing control and breathing-hold exercises, and Relaxation techniques:
Study: NCT04841265

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.
Study: NCT06233656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Description: Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing.
Study: NCT05542641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: real versus sham rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: real versus sham rTMS
Study: NCT04674956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel(Albumin Bound) and Gemcitabine
Description: Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel(Albumin Bound) and Gemcitabine
Description: Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 200mg, D1; every 21 days as a cycle.
Study: NCT05389267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kinezodianone R hydrochloride
Description: Eyedrops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05944432

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre 3 Continuous Glucose Monitoring System.
Description: Subjects will be randomised to use the FreeStyle Libre 3 system

Intervention type: DEVICE
Group type: OTHER
Intervention: Self monitoring of blood glucose
Description: Subjects will be randomised to continue with their current glucose monitoring system
Study: NCT05073315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Participants will receive subcutaneous (SC) injection of adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Participants will receive subcutaneous (SC) injection of adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 501
Description: Participants will receive SC injection of ABP 501
Study: NCT05559827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes \<10 G / L, and a third at day 29 if reticulocytes \<10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
Study: NCT05685186

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: To assess lung function

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: To assess lung function

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple Breath Washout (MBW)
Description: To measure Lung Clearance Index (LCI)

Intervention type: DIAGNOSTIC_TEST
Intervention: Mucociliary Clearance (MCC)
Description: To measure lung clearance after the inhalation of radiolabeled particles

Intervention type: DIAGNOSTIC_TEST
Intervention: Mucociliary Clearance (MCC)
Description: To measure lung clearance after the inhalation of radiolabeled particles

Intervention type: DIAGNOSTIC_TEST
Intervention: CT of the chest
Description: Low radiation to assess structural lung disease

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI of the chest
Description: To assess lung function and structural lung disease

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI of the chest
Description: To assess lung function and structural lung disease
Study: NCT05131061

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-Pentixafor PET/CT imaging
Description: 68Ga-Pentixafor PET/CT imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-Pentixafor PET/CT imaging
Description: 68Ga-Pentixafor PET/CT imaging
Study: NCT04702646

Intervention type: DRUG
Intervention: Bowel preparation before colonoscopy
Description: one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: colonoscopy will be performed to every patient included in the study
Study: NCT04682470

Intervention type: OTHER
Intervention: No intervention ; observational
Description: No intervention; observational
Study: NCT05868850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: auricular point sticking
Description: 1. Acupoint selection: Select Shenmen, spleen, stomach, liver, sympathetic, tongue, digestive system under the cortex, three focal, ear-back spleen.~2. Operation: Use 75% ethanol to disinfect auricular broad skin; To be dry, use tweezers to pick up the middle of the small square tape stuck with Wang do not line seeds, align the indentation and stick well, press gently with the finger abdomen, the strength to the patient feel acid swelling, pain and heat sense and can tolerate it.~3. Press frequency and course of treatment: it is asked to press 4 times a day, once in the morning, middle and evening before going to bed, 3-5 minutes each time, the duration of hospitalization for patients with chemotherapy is generally 3-5 days, intervention begins on the first day of chemotherapy medication, the day of discharge for patients to replace the other side of the ear acupoint, removed after 4 days of discharge. A total of 2 chemotherapy courses were treated.
Study: NCT05788679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine
Study: NCT05262101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 injection
Description: TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
Study: NCT06092151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: silver diamine fluoride - maximum 1 drop to be applied per visit (manufacturer advises this would treat up to 5 teeth)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual dental care
Description: Usual restorative or preventative care determined by the child's dentist - for examples fillings or crowns
Study: NCT05692440

Intervention type: DEVICE
Group type: OTHER
Intervention: Intracept Procedure
Description: Intraosseous radiofrequency ablation of the basivertebral nerve
Study: NCT05714761

Intervention type: DEVICE
Group type: OTHER
Intervention: Dexcom glucose sensor
Description: Use of a Dexcom G6 Pro
Study: NCT05605990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovative tourniquet (Acusense Nonpneumatic tourniquet)
Description: To use this innovative tourniquet before collecting blood samples, and setting IV catheter. We also use this innovative tourniquet to occlude the flow of blood.
Study: NCT04716543

Intervention type: DIAGNOSTIC_TEST
Intervention: ILI and COVID-19 detection
Description: All participants presenting with ILI symptoms will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.~All family members more than 6 months living with SARS-CoV-2 positive individuals will have will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.
Study: NCT05295589

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT05595434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Maastricht Stress Test (MAST), active condition.
Description: The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the active condition, participants have to switch between immersion of the hand into cold water and complex mental arithmetic operations.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Acute Maastricht Stress Test (MAST), placebo condition
Description: The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the placebo condition, participants have to switch between immersion of the hand into tempered water and simple mental arithmetic counts.
Study: NCT06475976

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest computed tomography (CT) with angiography
Description: A CT scan uses a doughnut-shaped machine to take x-rays in a circle around the body. CT scans help doctors learn about the structure of the lungs, heart, and blood vessels in the chest. A CT scan provides more information than regular x-rays. CT w/angiography - injection of intravenous contrast during the CT to image the blood vessels within the chest.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy with bronchoalveolar lavage
Description: During a bronchoscopy, a lung doctor inserts a small flexible camera into the breathing tube and main branches of the airways within the lungs. During the test, a small amount of sterile fluid is placed into the lung and then retrieved (lavage). This fluid is tested for evidence of infection.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: An echo uses sound waves to create computer pictures of the heart.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour esophageal pH (potential of hydrogen) - multichannel intraluminal impedance (MII) monitoring (reflux testing)
Description: 24 hour pH/MII testing is used to measure gastroesophageal reflux. A small feeding tube like catheter is passed through the nose or mouth into the esophagus. The catheter is used to measure the frequency and acidity of reflux episodes during a 24 hour monitoring period.
Study: NCT05545150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Imaging
Description: Clarix Imaging Volumetric Specimen Imager

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Per standard of care (SOC)
Study: NCT06063603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Pain Management
Description: Receive pain clinic referral

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Undergo CBT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Participate in focus group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive self-guided pain management education materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participate in exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Complete interview

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Receive massage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Relaxation
Description: Practice mindfulness

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain Therapy
Description: Receive pain treatment/medicine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Receive palliative care referral

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Undergo visits with PCM and CHW for pain management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral
Description: Receive pain management referrals

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spiritual Therapy
Description: Receive spiritual support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spiritual Care Referral
Description: Receive spiritual care referral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05216744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1000mg + doxycycline 100 mg
Description: Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefixime 800mg + doxycycline 100 mg
Description: Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
Study: NCT04633044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine
Description: The intervention with supplement will start during the first 48h after birth and will last for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
Study: NCT05279573

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 and/or botanical ingredient
Description: Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 and/or botanical ingredient
Description: Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 and/or botanical ingredient
Description: Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product consumption
Description: Product with identical characteristics to the experimental product. Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
Study: NCT05788679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor lymphocytes
Description: Donor lymphocytes in patients without immune suppression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapering of immune suppression
Description: Tapering of immune suppression in patients who are on immune suppressive drugs
Study: NCT06462092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Patients receive Sacituzumab Govitecan 10mg/kg by intravenous infusion on days 1 and 8. Treatment cycles are every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed intrathecal chemotherapy is administered by intracerebroventricular or lumbar puncture. Pemetrexed intrathecal chemotherapy is divided into induction, consolidation and maintenance phases. Induction therapy was first performed with a single dose of 15 mg twice a week for 2 weeks for a total of 4 doses. This was followed by consolidation therapy, 1 time per week for 4 consecutive weeks for a total of 4 times.
Study: NCT06095713

Intervention type: DRUG
Intervention: Pegunigalsidase-alfa
Description: Standard of care
Study: NCT06153303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.